SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Antibody Cat. No.: 9359

Availability: In stock

$0.00

 Price Options

* Required Fields

$0.00
psi-iconSpecifications
HOST SPECIES:Rabbit
SPECIES REACTIVITY: Virus
HOMOLOGY: Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (25%)
IMMUNOGEN: Anti-SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Antibody (9359) was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.

The immunogen is located within 650-700 amino acids of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.
TESTED APPLICATIONS: ELISA, WB
APPLICATIONS: WB: 1 μg/mL.

Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody can specifically detect SARS-CoV-2 UK Variant (B.1.1.7) Spike S1 protein, but not SARS-CoV-2 WT Spike S1 protein by ELISA. It can also detect mutant peptide (681H), but not WT peptide (681P). All other applications and species not yet tested.

psi-iconProperties
PURIFICATION:SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Antibody is affinity chromatography purified via peptide column.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:S
ALTERNATE NAMES:SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
ACCESSION NO.:QHD43416
PROTEIN GI NO.:1791269090
GENE ID:43740568
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.
REFERENCES:1) Duchene et al. Virus Evolution 6(2): veaa061.
2) Gu et al. Science 369(6511):1603-1607
3) Hoffmann et al. Molecular Cell 78(4):779-784.e5
4) Davies et al. Science 372(6538):eabg3055.
5) Davies et al. Nature. 593(7858):270-274.
6) Graham, et al. The Lancet Public Health. 6(5): e335-e345.
7) Horby et al. New & Emerging Threats Advisory Group. 2020;91:264-266.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.